These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19931380)

  • 1. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.
    Patel SM; Atmar RL; El Sahly HM; Cate TR; Keitel WA
    Vaccine; 2010 Apr; 28(17):3025-9. PubMed ID: 19931380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.
    Patel SM; Atmar RL; El Sahly HM; Guo K; Hill H; Keitel WA
    J Infect Dis; 2012 Oct; 206(7):1069-77. PubMed ID: 22891287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
    Carter C; Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Chen GL; Patel SM; Winokur P; Belshe R; Dekker CL; Graham BS; Ledgerwood JE;
    PLoS One; 2019; 14(9):e0222178. PubMed ID: 31532789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
    Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
    N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
    Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
    Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
    Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
    J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
    Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH
    Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.
    Brady RC; Treanor JJ; Atmar RL; Keitel WA; Edelman R; Chen WH; Winokur P; Belshe R; Graham IL; Noah DL; Guo K; Hill H
    Vaccine; 2009 Aug; 27(37):5091-5. PubMed ID: 19577636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.
    Ledgerwood JE; Wei CJ; Hu Z; Gordon IJ; Enama ME; Hendel CS; McTamney PM; Pearce MB; Yassine HM; Boyington JC; Bailer R; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
    Lancet Infect Dis; 2011 Dec; 11(12):916-24. PubMed ID: 21975270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K; Dhitavat J; Thantamnu N; Kosoltanapiwat N; Auayporn M; Jiang L; Puthavathana P; Pitisuttithum P
    Vaccine; 2017 Dec; 35(52):7339-7346. PubMed ID: 29157960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.